Total gray matter volume is reduced in individuals with bipolar disorder currently treated with atypical antipsychotics
| Autor: | Susanne Bengesser, Frederike T. Fellendorf, Robert Queissner, Alexander Maget, Carlo Hamm, Armin Birner, Stefan Ropele, Stephan Seiler, Christian Enzinger, Lukas Pirpamer, Martina Platzer, Hans-Peter Kapfhammer, Hannes Deutschmann, Rene Pilz, Melanie Lenger, Nina Dalkner, Eva Z. Reininghaus, Nicole Hinteregger, Marton Magyar, Bernd Reininghaus |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male medicine.medical_specialty Bipolar Disorder Dose Gray (unit) 03 medical and health sciences Drug treatment 0302 clinical medicine Internal medicine Medicine Humans In patient Bipolar disorder Longitudinal Studies Gray Matter Analysis of covariance business.industry Brain Middle Aged medicine.disease Magnetic Resonance Imaging 030227 psychiatry Substance abuse Psychiatry and Mental health Clinical Psychology Cross-Sectional Studies Female Psychopharmacology business 030217 neurology & neurosurgery Antipsychotic Agents |
| Zdroj: | Journal of affective disorders. 260 |
| ISSN: | 1573-2517 |
| Popis: | Background/Aims Recent evidence indicates that the intake of atypical antipsychotics (AAP) is associated with gray matter abnormalities in patients with psychiatric disorders. We explored if patients with bipolar disorder (BD) who are medicated with AAP exhibit total gray matter volume (TGV) reduction compared to BD individuals not medicated with AAP and healthy controls (HC). Methods In a cross-sectional design, 124 individuals with BD and 86 HC underwent 3T-MRI of the brain and clinical assessment as part of our BIPFAT-study. The TGV was estimated using Freesurfer. We used univariate covariance analysis (ANCOVA) to test for normalized TGV differences and controlled for covariates. Results ANCOVA results indicated that 75 BD individuals taking AAP had significantly reduced normalized TGV as compared to 49 BD not taking AAP (F = 9.995, p = .002., Eta = 0.084) and 86 HC (F = 7.577, p = .007, Eta = 0.046). Limitations Our cross-sectional results are not suited to draw conclusions about causality. We have no clear information on treatment time and baseline volumes before drug treatment in the studied subjects. We cannot exclude that patients received different psychopharmacologic medications prior to the study point. We did not included dosages into the calculation. Many BD individuals received combinations of psychopharmacotherapy across drug classes. We did not have records displaying quantitative alcohol consumption and drug abuse in our sample. Conclusions Our data provide further evidence for the impact of AAP on brain structure in BD. Longitudinal studies are needed to investigate the causal directions of the proposed relationships. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect